secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nexentis Technologies Inc. (NXTS)
CIK:        0001789192
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001493152-25-008294
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

N2OFF signs definitive agreement to acquire MitoCareX Bio in stock-cash deal
----------------------------------------------------------------------------

- N2OFF will pay $700,000 cash to SciSparc for 4,961 shares and issue common stock totaling 40% of fully diluted capital to all sellers.
- Sellers eligible for milestone-based issuance of up to 25% additional common stock and 30% of N2OFF financing proceeds capped at $1.6M over 5 years.
- N2OFF commits initial $1M investment in MitoCareX plus ongoing funding; MitoCareX becomes wholly-owned subsidiary upon closing.
- Transaction subject to N2OFF stockholder approval; board members Amitay Weiss and Liat Sidi also serve on SciSparc board (related party).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789192/000149315225008294/0001493152-25-008294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789192/000149315225008294/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-008294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer